Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 183

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms

Freund‐Levi, Yvonne, Basun, Hans, Cederholm, Tommy, Faxén‐Irving, Gerd, Garlind, Anita, Grut, Mikaela, Vedin, Inger, Palmblad, Jan, Wahlund, Lars‐Olof, Eriksdotter‐Jönhagen, Maria · 2008 · International Journal of Geriatric Psychiatry

Abstract

Background: Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega‐3 fatty acids (ω 3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An association with APOE ω 4 carriers and neuropsychiatric symptoms in AD has also been suggested. Objective: To determine effects of dietary ω 3 supplementation to AD patients with mild to moderate disease on psychiatric and behavioral symptoms, daily functions and a possible relation to APOE genotype. Methods: Randomized, double‐blind, placebo‐controlled clinical trial where 204 AD patients (74 ± 9 years) with acetylcholine esterase inhibitor treatment and a MMSE >15 points were randomized to daily intake of 1.7 g DHA and 0.6 g EPA (ω 3 group) or placebo for 6 months. Then, all received the ω 3 supplementation for 6 more months. Neuropsychiatric symptoms were measured with Neuropsychiatric Inventory (NPI) and Montgomery Åsberg Depression Scale (MADRS). Caregivers burden and activities of daily living (Disability Assessment for Dementia, DAD) were also assessed. Results: One hundred and seventy‐four patients fulfilled the trial. 72% were APOEω 4 carriers. No significant overall treatment effects on neuropsychiatric symptoms, on activities of daily living or on caregiver's burden were found. However, significant positive treatment effects on the scores in the NPI agitation domain in APOEω 4 carriers (p = 0.006) and in MADRS scores in non‐APOEω 4 carriers (p = 0.005) were found. Conclusions: Supplementation with ω 3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms (assessed by MADRS) in non‐APOEω 4 carriers and agitation symptoms (assessed by NPI) in APOEω 4 carriers. ClinicalTrials.gov identifier: NCT00211159 Copyright © 2007 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.1857

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 183

Metadata

Authors
Freund‐Levi, Y., Basun, H., Cederholm, T., Faxén‐Irving, G., Garlind, A., Grut, M., Vedin, I., Palmblad, J., Wahlund, L., & Eriksdotter‐Jönhagen, M.
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2007-06-21
Volume
23
Issue
2
Pages
161-169
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W1991670228
Cited by
183
References
9
FWCI
10.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. https://app.cochat.ai/papers/10.1002/gps.1857
The paper
Freund‐Levi, Y., Basun, H., Cederholm, T., Faxén‐Irving, G., Garlind, A., Grut, M., Vedin, I., Palmblad, J., Wahlund, L., & Eriksdotter‐Jönhagen, M. (2008). Omega‐3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.1857

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.